Stay updated with breaking news from Advanced Hematologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The expert panel shares emerging data on an engineered, allogeneic cell-based therapy administered as part of conditioning for allo-HSCT in patients with relapsed, refractory, or high-risk hematologic cancers.
CAMBRIDGE, Mass., Dec. 01, 2023 -- Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene...
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal
/PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that data from its oncology portfolio will be presented at...
– Achieved significant clinical progress for UltraCAR-T® and AdenoVerse™ investigational therapeutics in 2022 – – Presented positive clinical data for...